US authorities looking into price fixing in the generics industry are now investigating 16 companies and the price of at least 300 drugs, according to a press report.
Indivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the door to generic competition and sparking a run on its shares.
Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS.
Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD)
It all looked so good in 2011 when Eli Lilly agreed a deal with French biotech Adocia to develop an ultra-rapid insulin, in a deal worth up to $165 million.